Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2014

View Archived Issues

Phase II of RUTI vaccine to prevent active tuberculosis

New clinical data on alirocumab for hypercholesterolemia presented

RG-7287 inhibits tumor growth in xenograft models

Selvita's novel dual Mnk1/2 inhibitors show potential in preclinical models of cancer

Adocia reports results from phase IIa study of ultra-fast-acting BioChaperone lispro

Preliminary data reported for clinical study of UX-003 in mucopolysaccharidosis type VII

Antibody-drug conjugate collaboration between PolyTherics and MacroGenics extended

Chemilia discloses new tubulin polymerization inhibitors for cancer

Abbott completes enrollment in three further trials of Absorb

New Notch signaling inhibitors designed by Bristol-Myers Squibb

Sofosbuvir/GS-5816 gives SVR12 rates > 90% across all HCV genotypes

Pfizer discloses novel Abeta production inhibitors

GlaxoSmithKline presents promising preclinical data for GSK-2878175

Vivolux present agents for solid tumor treatment

Novel tankyrase inhibitors disclosed by Cellzome

Impax resubmits NDA for IPX-066

PCI Biotech announces completion of first dose cohort in phase I/II cholangiocarcinoma trial

German scientists disclose new MetAP 2 inhibitors

Lytix Biopharma forms Pharmasum Therapeutics to focus on dementia

Study will evaluate TSO in pediatric patients with autism spectrum disorder

Improved detection of localized prostate cancer with technetium Tc 99m trofolastat

Protocol for phase IIb study of metadoxine extended release sent to FDA

CHART-1 trial of C-Cure authorized to begin in Ireland

Cytos immunomodulator fails to achieve primary endpoint in phase IIb asthma study

Merrion to initiate pivotal phase III study of oral zoledronic acid in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...